共查询到20条相似文献,搜索用时 34 毫秒
1.
《Hematology (Amsterdam, Netherlands)》2013,18(5):261-266
AbstractUp to 60% of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) do not respond to second-line (salvage) chemotherapy and hence are not offered autologous hematopoietic cell transplantion (AHCT). The utility of further salvage chemotherapy in an attempt to proceed with AHCT remains undefined. The authors reviewed 201 patients with DLBCL relapsed/refractory to anthracycline-based chemotherapy who received first-line salvage chemotherapy containing cis-platinum. Of the 120 non-responders to first-line platinum-based salvage chemotherapy, 73 received second-line salvage chemotherapy. The response rate to second-line salvage chemotherapy was 14%. Factors predicting lack of response were progression on primary therapy (p = 0·007), abnormal lactate dehydrogenase findings (p = 0·0027) and tumor bulk (p = 0·013) at second progression. Eight patients who responded received AHCT and appeared to have comparable survival to those transplanted after one salvage regimen. The authors conclude that the utility of second-line salvage chemotherapy is low, and that it is best reserved for patients demonstrating initial anthracycline sensitivity and low tumor burden. 相似文献
2.
Moore S Kayani I Peggs K Qian W Lowry L Thomson K Linch DC Ardeshna K 《British journal of haematology》2012,157(5):543-552
Patients with relapsed or refractory lymphoma can be cured with stem cell transplantation if they are shown to have disease that is responsive to salvage chemotherapy. Patients who fail to respond to first-line salvage chemotherapy tend to do very poorly. Here we report on 39 such patients who received mini-BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy as second or subsequent-line salvage chemotherapy. Fifty-six percent of these patients had primary refractory disease and a further 28% had responses to first-line therapy that lasted <12 months. Seventy-two percent had progressive disease following the salvage chemotherapy administered immediately prior to mini-BEAM and the remaining 28% had stable disease. Overall there was a 38% response to mini-BEAM (complete response = 28%, partial response = 10%). Patients with Hodgkin lymphoma (HL) had a higher response rate compared to those with diffuse large B cell lymphoma (DLBCL) (63% vs. 20%). Seventy-four percent of HL patients were able to proceed to transplantation compared with 30% of patients with DLBCL. Mini-BEAM is a very effective bridge to transplantation in very poor risk patients with HL who have failed to respond to first-line salvage chemotherapy. Its efficacy in non-Hodgkin lymphoma is more modest. 相似文献
3.
Villa D Seshadri T Puig N Massey C Tsang R Keating A Crump M Kuruvilla J 《Haematologica》2012,97(5):751-757
Background
The management of patients with relapsed or refractory Hodgkin’s lymphoma who achieve less than a partial response to first-line salvage chemotherapy is unclear. The objective of this study was to evaluate response and outcomes to second-line salvage and autologous stem cell transplantation in patients not achieving a complete or partial response to platinum-containing first-line salvage chemotherapy.Design and Methods
Consecutively referred transplant-eligible patients with relapsed/refractory Hodgkin’s lymphoma after primary chemotherapy received gemcitabine, dexamethasone, and cisplatin as first salvage chemotherapy. Those achieving a complete or partial response, and those with a negative gallium scan and stable disease with bulk <5 cm proceeded to high-dose chemotherapy and autologous stem cell transplantation. Patients with progressive disease or stable disease with a positive gallium scan or bulk ≥5 cm were given second salvage chemotherapy with mini-BEAM (carmustine, etoposide, cytarabine, melphalan). Patients who responded (according to the same definition) proceeded to autologous stem cell transplantation.Results
One hundred and thirty-one patients with relapsed/refractory Hodgkin’s lymphoma received first-line salvage gemcitabine, dexamethasone, and cisplatin; of these patients 99 had at least a partial response (overall response rate 76%). One hundred and twelve (85.5%) patients proceeded to autologous stem cell transplantation, while the remaining 19 (14.5%) patients received mini-BEAM. Among these 19 patients, six had at least a partial response (overall response rate 32%), and nine proceeded to autologous stem cell transplantation. The remaining ten patients received palliative care. Seven of the nine patients transplanted after mini-BEAM had a subsequent relapse. Patients receiving second salvage mini-BEAM had poor outcomes, with a 5-year progression-free survival rate of 11% and a 5-year overall survival rate of 20%.Conclusions
Patients who require a second salvage regimen to achieve disease control prior to autologous stem cell transplantation have a relatively poor outcome and should be considered for alternative treatment strategies. 相似文献4.
《British journal of haematology》2017,176(4):591-599
Rituximab‐containing salvage chemotherapy followed by high‐dose therapy and autologous stem cell transplant (ASCT ) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B‐cell lymphoma (DLBCL ). However, its role in those patients achieving less than a complete response to first‐line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant‐eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high‐dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3‐year overall and progression‐free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long‐term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high‐dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL , particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population. 相似文献
5.
Moskowitz CH Zelenetz AD Kewalramani T Hamlin P Lessac-Chenen S Houldsworth J Olshen A Chaganti R Nimer S Teruya-Feldstein J 《Blood》2005,106(10):3383-3385
A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pretreatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL. 相似文献
6.
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma 总被引:1,自引:0,他引:1
Kewalramani T Zelenetz AD Teruya-Feldstein J Hamlin P Yahalom J Horwitz S Nimer SD Moskowitz CH 《British journal of haematology》2006,134(2):202-207
Autologous transplantation (ASCT) is the standard of care for chemosensitive relapsed or primary refractory aggressive lymphoma, but little is known about its efficacy in the subset of patients with peripheral T-cell lymphoma (PTCL). We undertook a retrospective review of patients with PTCL who underwent ASCT for relapsed or refractory disease after responding to second-line therapy, excluding patients with indolent histologies and those with anaplastic lymphoma kinase (ALK) expressing anaplastic large cell lymphoma. The results of 24 patients with PTCL were compared with those of 86 consecutive patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). With a median follow-up time of 6 years for surviving patients with PTCL and DLBCL, the 5-year progression-free survival (PFS) rates for PTCL and DLBCL patients were 24% and 34% respectively (P = 0.14); the corresponding overall survival (OS) rates were 33% and 39% respectively. There were no significant differences between the two groups with respect to time to disease progression or survival after progression. The second-line age-adjusted international prognostic index was the only variable prognostic for PFS and OS in a multivariate analysis. The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL. 相似文献
7.
Andrea Borgerding Justin Hasenkamp Bertram Glaß Gerald Wulf Lorenz Trümper 《Annals of hematology》2010,89(3):283-289
Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been
defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective
outcome analysis of second-line immunochemotherapy with rituximab. In 28 patients with relapsed or refractory diffuse large
B cell lymphomas, first-line immunochemotherapy had induced objective responses in 18 patients. Nine of 28 patients responded
to rituximab containing salvage therapy, leading to a median overall survival of 243 days after start of second immunochemotherapy.
Long-term disease free survivors (1,260 and 949 days) were restricted to the group of twelve patients that had received allogeneic
stem cell transplantation as consolidation therapy. In 21 patients with relapsed mantle cell lymphomas (MCL), 19 patients
had reached remissions with first-line therapy. Of those, 16 patients experienced responses to salvage therapy with a median
overall survival of 226 days. Noteworthy, none of patients with initial non-responding disease reached a remission with second
immunochemotherapy. Seven patients with MCL stayed free from progression after high-dose therapy with autologous or allogeneic
stem cell transplantation in two and five cases, respectively. In summary, responses to repeated immunotherapy with rituximab
were observed in approximately one third and two thirds of initially responding patients with aggressive B cell lymphoma and
mantle cell lymphoma, respectively, but not in primarily refractory disease. Lasting remissions were achieved only by high-dose
chemotherapy with stem cell transplantation. 相似文献
8.
Michael Dickinson Rosemary Hoyt Andrew W. Roberts Andrew Grigg John F. Seymour H. Miles Prince Jeff Szer David Ritchie 《British journal of haematology》2010,150(1):39-45
The utility of [18F]fluoro‐2‐deoxy‐ d ‐glucose positron‐emission tomography (FDG‐PET) for predicting outcome after autologous stem cell transplantation (ASCT) for diffuse large B cell lymphoma (DLBCL) is uncertain – existing studies include a range of histological subtypes or have a limited duration of follow‐up. Thirty‐nine patients with primary‐refractory or relapsed DLBCL with pre‐ASCT PET scans were analysed. The median follow‐up was 3 years. The 3‐year progression‐free survival (PFS) for patients with positive PET scans pre‐ASCT was 35% vs. 81% for those who had negative PET scans (P = 0·003). The overall survival (OS) in these groups was 39% and 81% (P = 0·01), respectively. In a multivariate analysis, PET result, number of salvage cycles and the presence of relapsed or refractory disease were shown to predict a longer PFS; PET negativity (P = 0·04) was predictive of a longer OS. PET is useful for defining those with an excellent prognosis post‐ASCT. Although those with positive scans can still be salvaged with current treatments, PET may useful for selecting patients eligible for novel consolidation strategies after salvage therapies. 相似文献
9.
Eliza A. Hawkes Sarah Barton David Cunningham Clare Peckitt Sue Chua Andrew Wotherspoon Alan Horwich Mike Potter Mark Ethel Claire Dearden Ian Chau 《Annals of hematology》2014,93(5):827-834
Hodgkin lymphoma (HL) is a relatively chemosensitive malignancy. However, for those who relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy. Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity. Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting. In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m2 day (D)1, D8 and D15; methylprednisolone 1,000 mg D1–5; and cisplatin 100 mg/m2 D15, every 28 days (GEM-P) were included. Demographic, survival, response and toxicity data were recorded. Forty-one eligible patients were identified: median age 27. One hundred and twenty-two cycles of GEM-P were administered in total (median 3 cycles; range 1–6). Twenty of 41 (48 %) patients received GEM-P as second-line treatment and 11/41 (27 %) as third-line therapy. Overall response rate (ORR) to GEM-P in the entire cohort was 80 % (complete response (CR) 37 %, partial response 44 %) with 14/15 CR confirmed as a metabolic CR on PET and ORR of 85 % in the 20 second-line patients. The most common grade 3/4 toxicities were haematological: neutropenia 54 % and thrombocytopenia 51 %. Median follow-up from the start of GEM-P was 4.5 years. Following GEM-P, 5-year progression-free survival was 46 % (95 % confidence interval (CI), 30–62 %) and 5-year overall survival was 59 % (95 % CI, 43–74 %). Fourteen of 41 patients proceeded directly to autologous transplant. GEM-P is a salvage chemotherapy with relatively high response rates, leading to successful transplantation in appropriate patients, in the treatment of relapsed or refractory HL. 相似文献
10.
Yonemori K Yamaguchi U Kaneko M Uno H Takeuchi M Ando M Fujiwara Y Hosono A Makimoto A Hasegawa T Yokoyama R Nakatani F Kawai A Beppu Y Chuman H 《Journal of cancer research and clinical oncology》2008,134(3):389-395
Purpose There is some unknown reason Ewing family of tumors (EFTs) is much less common on Asia and Africa than in the Western Caucasian
population. This study analyzed the prediction of response and prognostic factors for Ewing family of tumors (EFTs) in an
Asian population with a low incidence.
Methods We retrospectively reviewed 94 patients with EFTs between 1978 and 2006. Fifteen patients received local therapy only. Statistical
analyses were performed for 79 patients, including those who received systemic chemotherapy, to identify factors related to
chemotherapy responsiveness, event-free survival, and overall survival.
Results Of the 79 patients whose records were analyzed, the 5-year event-free rate and overall survival (OS) rate were 41 and 54%,
respectively. The response rate to first-line chemotherapy was 61% in 70 patients with assessable lesions. A significant predictor
of response was existence of a non-pelvic primary tumor (P = 0.04). Significant prognostic factors for OS were age, performance status, and metastases at the time of diagnosis (P < 0.01, respectively). Fifty-four patients had disease progression or recurrence after first-line treatment. The time to
progression was 3.4 months after salvage treatment. Progression during first-line treatment was significantly associated with
time to progression after salvage treatment (P = 0.01). All patients treated without chemotherapy in first-line treatment were recurred with poor prognosis.
Conclusion A non-pelvic primary tumor was a favorable predictor of responsiveness to chemotherapy. Chemo-resistant patients might less
benefit from second line chemotherapy. Chemotherapy in first-line treatment should not be omitted, even if primary tumor was
extirpated completely. 相似文献
11.
Ardeshna KM Kakouros N Qian W Powell MG Saini N D'Sa S Mackinnon S Hoskin PJ Goldstone AH Linch DC 《British journal of haematology》2005,130(3):363-372
This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first-line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy. The outcome of 57 patients [Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional-dose salvage therapy was analysed. Sixteen patients had a partial response (PR) to 1 degrees ST, but subsequently received 2 degrees ST because the PR was judged to be inadequate (iPR) because of persisting disease bulk or marrow infiltration. Of these 16 patients, 10 (63%) continued to respond to 2 degrees ST. Of the 15 patients who had stable disease following 1 degrees ST, 5 (33%) responded to 2 degrees ST. Only one of the 24 (4%) with progressive disease (PD) following 1 degrees ST, responded to 2 degrees ST. 25 of the 57 patients ultimately underwent stem cell transplantation. The 2-year progression-free survival (PFS) and the 3-year overall survival (OS) for all patients was 24% and 31%, respectively. Long-term survival was highly dependent on response to 1 degrees ST (P = 0.0001); in patients with PD following 1 degrees ST, the PFS and OS at 3 years was only 4%. This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored. 相似文献
12.
《British journal of haematology》2018,182(5):633-643
Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients still experience relapses. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second‐line treatment for relapsed and refractory (R/R) DLBCL. However, half of the patients will not be eligible for transplantation due to ineffective salvage treatment, and the other half will relapse after ASCT. In randomized studies, no salvage chemotherapy regimen is superior to another. The outcomes are affected by the secondary International Prognostic Index at relapse and various biological factors. The strategy is less clear in patients who require third‐line treatment. A multicohort retros pec tive non‐Hodgkin lymphoma research (SCHOLAR‐1) study conducted in 636 patients with refractory DLBCL showed an objective response rate of 26% (complete response 7%) to the next line of therapy with a median overall survival of 6·3 months. In the case of a response followed by transplantation, long‐term survival can be achieved in DLBCL patients. There is clearly a need for new drugs that improve salvage efficacy. Encouraging results have been reported with chimeric antigen receptor ‐T cell engineering, warranting further studies in a well‐defined control group of refractory patients. The Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) was used as a handy framework to build the discussion. 相似文献
13.
Moon Ki Choi Eun Suk Kang Dae Won Kim Yonug Hyeh Ko Hyeri Seok Jin Hong Park Dae Hee Pyo Do Hoon Lim Seok Jin Kim Won Seog Kim 《International journal of hematology》2013,98(3):346-354
No salvage treatment strategy has been established for relapsed or refractory primary central nervous system lymphoma (PCNSL). We compared treatment outcomes of patients who underwent salvage chemotherapy with or without autologous stem cell transplantation (ASCT). We retrospectively analyzed PCNSL patients who were histologically diagnosed with diffuse large B-cell lymphoma. All patients relapsed after high-dose methotrexate (MTX)-based chemotherapy, or were refractory to high-dose MTX. Patients were treated with salvage chemotherapy, such as ICE/D (ifosfamide, carboplatin, etoposide, and dexamethasone) or high-dose MTX. High-dose chemotherapy containing thiotepa and busulfan followed by ASCT was performed if patients were eligible for ASCT after salvage treatment. Forty-five patients (35 relapsed and 10 refractory) received ICE/D or high-dose MTX. Despite the important difference that ICE/D was used predominantly for early relapsed or refractory patients, the two salvage treatments produced similar overall response rates [84.4 % (38/45) for ICE/D and 81.3 % (13/16) for high-dose MTX re-treatment]. Eighteen patients underwent ASCT, whereas 27 patients received salvage chemotherapy alone. The median progression-free survival of patients who underwent ASCT (19.5 months) was significantly better than that of patients who did not receive ASCT (6.7 months, P = 0.023). Multivariate analysis showed that refractoriness to initial treatment and no ASCT were significantly associated with poor survival outcome. Our study suggested that the combination of ifosfamide, carboplatin, etoposide, and dexamethasone may represent a feasible salvage treatment option for relapsed or refractory PCNSL, and that high-dose chemotherapy containing thiotepa and busulfan followed by ASCT may be effective for patients with a favorable toxicity profile. 相似文献
14.
目的 探讨晚期非小细胞肺癌患者化疗前后血清乳酸脱氢酶(LDH)水平的变化及其与化疗疗效和疾病进展的关系.方法 57例晚期非小细胞肺癌患者接受标准一线化疗方案,部分患者接受二线化疗方案治疗,根据化疗前后肺部CT影像学改变进行分析,同时监测化疗过程中血清LDH水平的变化,分析血清LDH水平的变化及其与化疗疗效和疾病进展的关系.结果 肺癌患者血清LDH水平显著高于正常健康志愿者;一线方案化疗有效者LDH水平较化疗前降低(P<0.05),而一线方案化疗失败患者LDH水平较化疗前升高(P<0.01);肿瘤复发时和疾病控制期相比LDH显著升高(P<0.01);疾病进展患者经二线化疗方案治疗有效组LDH水平较化疗前降低(P<0.05),在二线化疗失败组LDH水平较化疗前明显升高(P<0.05).结论 血清中LDH水平变化可反映肺癌化疗疗效,且可用于监测肺癌复发. 相似文献
15.
目的 探讨晚期非小细胞肺癌患者化疗前后血清乳酸脱氢酶(LDH)水平的变化及其与化疗疗效和疾病进展的关系.方法 57例晚期非小细胞肺癌患者接受标准一线化疗方案,部分患者接受二线化疗方案治疗,根据化疗前后肺部CT影像学改变进行分析,同时监测化疗过程中血清LDH水平的变化,分析血清LDH水平的变化及其与化疗疗效和疾病进展的关系.结果 肺癌患者血清LDH水平显著高于正常健康志愿者;一线方案化疗有效者LDH水平较化疗前降低(P<0.05),而一线方案化疗失败患者LDH水平较化疗前升高(P<0.01);肿瘤复发时和疾病控制期相比LDH显著升高(P<0.01);疾病进展患者经二线化疗方案治疗有效组LDH水平较化疗前降低(P<0.05),在二线化疗失败组LDH水平较化疗前明显升高(P<0.05).结论 血清中LDH水平变化可反映肺癌化疗疗效,且可用于监测肺癌复发. 相似文献
16.
Sirohi B Cunningham D Norman A Last K Chau I Horwich A Oates J Chong G Wotherspoon A 《Hematology (Amsterdam, Netherlands)》2007,12(2):149-153
This is the first report of the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) with Rituximab (GEM-PR) for diffuse large B-cell lymphoma (DLBCL). Thirty-nine patients with relapsed or refractory DLBCL in this study received GEM-P with (n = 24) or without Rituximab (n = 15) 64% patients had Stage III/IV disease. The overall response rate (ORR) was 59% (95% CI 42.1-74.4); 11/39 (28%) patients attained complete response. Patients received a median of two cycles (1-4) of treatment. For GEM-PR group, the ORR was 67% (95% CI 45-84%) compared to 47% (95% CI 21-73%) in GEM-P alone. one-year progression-free survival was 51% (95% CI 28-69%) in GEM-PR group compared to 27% (95% CI 8-49%) in GEM-P alone (P = 0.04). GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes. 相似文献
17.
Chen CH Chen SW Shen WL Chen TY Tsao CJ Huang WT 《International journal of hematology》2007,85(2):105-107
Anaplastic lymphoma kinase (ALK) expression exists in approximately 60% of anaplastic large cell lymphoma (ALCL) cases. Compared with the ALK-negative cases, ALK-positive cases are usually characterized by a good response to chemotherapy and a good prognosis. In the relapsed or refractory ALCL cases, high-dose chemotherapy followed by autologous stem cell transplantation has been widely used as a salvage therapy. However, 40% of patients who received transplants after more than 2 complete remissions eventually experienced disease progression, despite receiving autologous stem cell transplantation. Allogeneic stem cell transplantation has been proposed as a therapeutic option in refractory ALCL cases, but clinical reports of adult patients are rare. Herein, we report the case of an adult with refractory ALK-positive ALCL who was successfully treated with salvage high-dose chemotherapy followed by allogeneic stem cell transplantation. 相似文献
18.
M C Fernández-Jiménez M A Canales E Ojeda J G de Bustos M J Aguado F Hernández-Navarro 《Haematologica》1999,84(11):1007-1011
BACKGROUND AND OBJECTIVE: High-dose chemotherapy and autologous bone marrow transplantation (ABMT) has become the standard approach for most patients with relapsed or refractory Hodgkin's disease. Disease status at transplant has been correlated with outcome following ABMT. In light of this, we employ mini-BEAM (BCNU, etoposide, cytarabine and melphalan) salvage therapy in order to achieve a state of minimal residual disease prior to transplantation. DESIGN AND METHODS: From February 1992 to June 1998 twenty-four patients receiving mini-BEAM therapy for resistance or relapse of their Hodgkin's disease were included. Four patients had obtained no response with initial chemotherapy (refractory), eight had obtained an incomplete response, seven were in first relapse and five in second or subsequent relapse. Fifteen patients received mini-BEAM as first salvage chemotherapy regimen. The remaining nine patients had previously been exposed to a median of one salvage regimen. Patients received a median of three cycles of mini-BEAM. RESULTS: Sixteen patients achieved complete remission and four partial remission, yielding an overall response rate of 83%. No significant differences in response were observed between patients who received mini-BEAM as initial salvage therapy and those who had received a prior salvage regimen. Eighteen out of the twenty responding patients went on to intensive therapy and peripheral blood stem cell transplantation. With a median follow-up of 52 months, the cumulative probability of 7-year overall survival is 71% for the responders and that of the 6-year disease-free survival is 42%. No treatment-related deaths were observed. INTERPRETATION AND CONCLUSIONS: Mini-BEAM is an effective salvage regimen with moderate toxicity that may be useful for cytoreduction prior to stem cell procedures. 相似文献
19.
Bhawna Sirohi David Cunningham Andy Norman Kim Last Ian Chau Alan Horwich 《Hematology (Amsterdam, Netherlands)》2013,18(2):149-153
This is the first report of the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) with Rituximab (GEM-PR) for diffuse large B-cell lymphoma (DLBCL). Thirty-nine patients with relapsed or refractory DLBCL in this study received GEM-P with (n = 24) or without Rituximab (n = 15) 64% patients had Stage III/V disease. The overall response rate (ORR) was 59% (95% CI 42.1–74.4); 11/39 (28%) patients attained complete response. Patients received a median of two cycles (1–4) of treatment. For GEM-PR group, the ORR was 67% (95% CI 45–84%) compared to 47% (95% CI 21–73%) in GEM-P alone. one-year progression-free survival was 51% (95% CI 28–69%) in GEM-PR group compared to 27% (95% CI 8–49%) in GEM-P alone (P = 0.04). GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes. 相似文献
20.
Sarah J. Nagle Kaitlin Woo Stephen J. Schuster Sunita D. Nasta Edward Stadtmauer Rosemarie Mick Jakub Svoboda 《American journal of hematology》2013,88(10):890-894
Salvage chemotherapy followed by autologous stem cell transplant (ASCT) remains the current standard of care for patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) with chemosensitive disease. The addition of rituximab results in improved overall survival (OS) after first‐line treatment, but cure rates of salvage therapy with ASCT are inferior when compared to historical controls. Historically, patients with DLBCL with disease progression following ASCT have had an extremely poor prognosis with a median OS of 3 months. However, there are little data regarding outcomes in the rituximab era. We performed a retrospective study of 56 patients with relapsed or refractory DLBCL with prior exposure to rituximab who had disease progression following ASCT. The median OS from progression following ASCT for the cohort was 9.9 months (95% CI: 5.3–13.1 months). Patients who progressed less than 1 year from ASCT had a significantly shorter OS than those who progressed at 1 year or greater from ASCT (8.2 vs. 26.7 months, P = 0.01). Patients with at least stable disease following ASCT had a longer OS than those who progressed immediately after ASCT (12.3 vs. 5.3 months, P = 0.01). Other factors associated with OS were International Prognostic Index (IPI) (P = 0.01) and LDH level (P = 0.0003) at the time of progression following ASCT. In the rituximab era, the prognosis for patients with disease progression following ASCT remains poor, but is improved when compared with historical controls. Ultimately, more work needs to be done to develop novel therapeutic strategies tailored to individual patients in this heterogeneous population. Am. J. Hematol. 88:890–894, 2013. © 2013 Wiley Periodicals, Inc. 相似文献